NCT06578455View on ClinicalTrials.gov

A Pharmacokinetic Study to Compare CBD-NE to Epidyolex in Healthy Adult Volunteers Under Both Fed and Fasted Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 30, 2024

Primary Completion Date

November 20, 2024

Study Completion Date

December 16, 2024

Conditions
CBD PharmacokineticsHealthy Participants
Interventions
DRUG

Cannabidiol (CBD) Powder

66.68 mg CBD per capsule for a total of 400 mg CBD per serving

DRUG

Cannabidiol 100 MG/ML [Epidiolex]

100 mg CBD/mL for a total of 400 mg CBD per serving

Trial Locations (1)

N1G0B4

Nutrasource Site (Apex Trials), Guelph

All Listed Sponsors
collaborator

Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

NETWORK

lead

DSM Nutritional Products, Inc.

INDUSTRY

NCT06578455 - A Pharmacokinetic Study to Compare CBD-NE to Epidyolex in Healthy Adult Volunteers Under Both Fed and Fasted Conditions | Biotech Hunter | Biotech Hunter